ARPA-H launches with ambitious mandate to transform health research like DARPA did for defense

In September 2022, the federal government formally launched a new agency with an unusual mandate: fund the kind of ambitious, risky science that most government institutions avoid. The Advanced Research Projects Agency for Health, or ARPA-H, arrived with a billion dollars in hand and a borrowed blueprint from the Defense Department's most celebrated innovation engine.

The agency's creation capped two years of planning that began with a simple observation: the Defense Advanced Research Projects Agency, or DARPA, had spent decades turning moonshot ideas into transformative technologies—the internet, GPS, and more recently the mRNA vaccine platform that Moderna would develop. If DARPA could do that for national security, why not health? President Biden appointed Renee Wegrzyn, a molecular biologist with a PhD from Georgia Tech and four and a half years of experience as a program manager at DARPA's Biological Technologies Office, to lead the effort. She had also worked at the Intelligence Advanced Research Projects Activity, another DARPA spinoff created in 2006. The pattern was clear: when the government wanted to move fast and think big, it looked to the DARPA model.

What makes ARPA-H structurally different from the National Institutes of Health or the National Science Foundation comes down to philosophy and speed. The NIH and NSF tend to fund foundational research with lower risk and longer timelines. DARPA, by contrast, employs roughly a hundred program managers—borrowed from universities and private companies for three to five years—who actively hunt for ideas, make aggressive funding decisions, and will terminate projects that miss promised milestones. They travel the country meeting scientists and experts, synthesizing what they learn into executable projects. Many DARPA initiatives fail or produce modest results, but the ones that succeed often reshape entire fields. The agency operates in the gap between slow government science and fast venture capital, willing to bet on ideas that are too ambitious for traditional funding but too early for private investment.

Wegrzyn's background suggested she understood this world. At DARPA's Biological Technologies Office, she had managed projects focused on genetic engineering and gene editing for biosecurity and public health—exactly the kind of boundary-pushing work the new health agency would need to pursue. She brought not just technical knowledge but institutional memory of how DARPA actually worked, which mattered because ARPA-H would face a challenge that DARPA had never quite confronted: it was being placed inside the NIH, not outside it. The theory was elegant—ARPA-H could borrow NIH's vast scientific networks and administrative infrastructure while maintaining the independence to move quickly. The reality would be messier. NIH and DARPA operate on fundamentally different assumptions about risk, timeline, and accountability. Making them coexist would require more than good intentions.

The immediate obstacles were concrete. Biden had requested $6.5 billion in funding for ARPA-H, but Congress had approved only $1 billion for the first year. That gap mattered not just for the agency's ambitions but for its credibility. A well-funded ARPA-H could signal to the scientific community that the government was serious about backing bold health research. A chronically underfunded one would send the opposite message. The second test would be hiring. The program managers were the engine of DARPA's success—their judgment, ambition, and willingness to take risks determined which ideas got funded and which got cut. What kind of people ARPA-H recruited, and from which fields, would reveal which health challenges the agency actually intended to prioritize. Cancer, diabetes, and Alzheimer's were named as targets, but the real priorities would emerge in the hiring decisions made in the months ahead.

As the agency began operations, three questions hung over it. First: could ARPA-H recruit and retain the kind of talented, risk-taking program managers that made DARPA work, or would the slower culture of NIH pull it toward caution? Second: could it genuinely operate as an independent entity within a much larger institution, or would bureaucratic gravity eventually slow it down? Third: would Congress fund it adequately, or would the agency spend its first years fighting for resources instead of pursuing breakthroughs? The model was proven. The mandate was clear. Whether ARPA-H could actually execute on its promise depended on decisions that were still being made.